Invest now
Dr. Lal PathLabs share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,924.15(-0.16%)August 7, 2026 15:29:24 PM IST
- NSE
- BSE
- Vol : 163.20 K (NSE + BSE)Last 20 day avg : 529.94 K
Dr. Lal PathLabs is trading -0.16% lower at Rs 1,924.15 as compared to its last closing price. Dr. Lal PathLabs has been trading in the price range of 1,947.00 & 1,915.00. Dr. Lal PathLabs has given 30.04% in this year & 2.62% in the last 5 days. Dr. Lal PathLabs has TTM P/E ratio 50.72 as compared to the sector P/E of 29.51.There are 25 analysts who have initiated coverage on Dr. Lal PathLabs. There are 9 analysts who have given it a strong buy rating & 10 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 169.50 Crores in its last quarter.Listed peers of Dr. Lal PathLabs include Apollo Hospitals Enterprise (1.90%), Max Healthcare Institute (-0.19%), Fortis Healthcare (2.67%).The Mutual Fund holding in Dr. Lal PathLabs was at 18.79% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Dr. Lal PathLabs was at 17.35% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 07 Aug 2026, 05:40 PM IST
- BetaLow volatility0.84Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.08The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.85Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation2.07The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Dr. Lal PathLabs News
Dr. Lal PathLabs Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | 8,980.50 | 1.90 | 1,29,125.81 | 64.93 | 13.39 | 0.23 | 53.80 |
| Max Healthcare Institute | 1,073.00 | -0.19 | 1,04,432.24 | 71.47 | 9.87 | 0.18 | 27.71 |
| Fortis Healthcare | 960.00 | 2.67 | 72,475.99 | 67.89 | 7.27 | 0.10 | 29.68 |
| Aster DM Healthcare | 875.00 | 3.62 | 45,703.64 | 102.55 | 9.26 | 0.49 | 44.74 |
| Narayana Hrudayalaya | 1,899.00 | 0.81 | 38,865.89 | 48.07 | 9.08 | 0.22 | 121.59 |
Mutual Fund Ownership
View allDr. Lal PathLabs Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-24 | Quarterly Results |
| 2026-04-30 | Audited Results & Final Dividend |
| 2026-01-30 | Quarterly Results & Interim Dividend |
| 2025-10-31 | Qtr Results, Int.Dividend & Bonus issue |
| 2025-07-31 | Quarterly Results, Dividend & Others |
About the company Dr. Lal PathLabs
- IndustryHealthcare Facilities
- ISININE600L01024
- BSE Code539524
- NSE CodeLALPATHLAB
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
Dr. Lal PathLabs Share Price FAQs
Dr. Lal PathLabs is trading at 1924.15 as on Fri Aug 07 2026 09:59:24. This is -0.16% lower as compared to its previous closing price of 1927.20.
The market capitalization of Dr. Lal PathLabs is 32209.22 Cr as on Fri Aug 07 2026 09:59:24.
The average broker rating on Dr. Lal PathLabs is Buy. The breakup of analyst rating is given below -
- 9 analysts have given a strong buy rating
- 10 analysts have given a buy rating
- 3 analysts have given a hold rating
- 3 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Dr. Lal PathLabs is 1950.45 whereas the 52 wk low is 1272.00
Dr. Lal PathLabs can be analyzed on the following key metrics -
- TTM P/E: 50.72
- Sector P/E: 29.51
- Dividend Yield: 0.83%
- D/E ratio: -
Dr. Lal PathLabs reported a net profit of 504.78 Cr in 2026.
The Mutual Fund Shareholding was 18.79% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Dr. Lal PathLabs QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.